Logo-ipp

Immunopathol Persa. 2021;7(2): e12. doi: 10.34172/ipp.2021.12

Editorial

Controversy with bromhexine in COVID-19; where we stand

Ramin Tolouian 1 * ORCID, Zuber D. Mulla 2 ORCID

Cited by CrossRef: 4

1- Mitev V, Mondeshki T, Miteva A, Tachkov K, Dimitrova V. COVID‐19 Prophylactic Effect of Bromhexine Hydrochloride. Immunity Inflam & Disease. 2026;14(4) [Crossref]
2- Mitev V, Dimitrova V, Miteva I, Tiholov R, Marinov K, Miteva A, Lilov A, Bilyukov R, Mihaylova Z, Ishkitiev N, Tachkov K, Mondeshki T. Pilot survey among patients taking bromhexine prophylactically against influenza. 2026;15(6):2296 [Crossref]
3- Mitev V. Comparison of treatment of COVID-19 with inhaled bromhexine, higher doses of colchicine and hymecromone with WHO-recommended paxlovid, molnupiravir, remdesivir, anti-IL-6 receptor antibodies and baricitinib. PHAR. 2023;70(4):1177 [Crossref]
4- Mondeshki T, Bilyukov R, Tomov T, Mihaylov M, Mitev V. Complete, Rapid Resolution of Severe Bilateral Pneumonia and Acute Respiratory Distress Syndrome in a COVID-19 Patient: Role for a Unique Therapeutic Combination of Inhalations With Bromhexine, Higher Doses of Colchicine, and Hymecromone. 2022; [Crossref]